Wall Street brokerages forecast that Millendo Therapeutics Inc (NASDAQ:MLND) will post earnings per share (EPS) of ($0.81) for the current quarter, Zacks reports. Zero analysts have provided estimates for Millendo Therapeutics’ earnings, with estimates ranging from ($0.81) to ($0.80). Millendo Therapeutics reported earnings per share of ($2.10) during the same quarter last year, which would indicate a positive year over year growth rate of 61.4%. The firm is scheduled to report its next quarterly earnings results on Thursday, August 8th.

According to Zacks, analysts expect that Millendo Therapeutics will report full year earnings of ($3.25) per share for the current financial year, with EPS estimates ranging from ($3.29) to ($3.20). For the next financial year, analysts forecast that the company will report earnings of ($3.03) per share, with EPS estimates ranging from ($3.39) to ($2.66). Zacks’ EPS averages are an average based on a survey of research analysts that cover Millendo Therapeutics.

Millendo Therapeutics (NASDAQ:MLND) last issued its earnings results on Wednesday, May 15th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.08).

A number of brokerages recently weighed in on MLND. Zacks Investment Research downgraded shares of ExlService from a “hold” rating to a “sell” rating in a research report on Wednesday. ValuEngine downgraded shares of Welbilt from a “hold” rating to a “sell” rating in a research report on Wednesday, June 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $23.25.

Several large investors have recently made changes to their positions in MLND. Private Advisors LLC boosted its holdings in Millendo Therapeutics by 9.1% in the 1st quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock valued at $229,000 after purchasing an additional 1,279 shares in the last quarter. Tibra Equities Europe Ltd acquired a new stake in shares of Millendo Therapeutics during the 1st quarter valued at approximately $303,000. Great Point Partners LLC acquired a new stake in shares of Millendo Therapeutics during the 4th quarter valued at approximately $10,240,000. Worth Venture Partners LLC acquired a new stake in shares of Millendo Therapeutics during the 4th quarter valued at approximately $206,000. Finally, Prosight Management LP acquired a new stake in shares of Millendo Therapeutics during the 4th quarter valued at approximately $2,041,000. 44.07% of the stock is owned by institutional investors and hedge funds.

Shares of Millendo Therapeutics stock traded down $0.41 during trading on Monday, reaching $10.67. The company had a trading volume of 39,931 shares, compared to its average volume of 105,008. The firm has a market capitalization of $142.87 million, a P/E ratio of -0.61 and a beta of 2.61. The firm’s fifty day simple moving average is $13.36. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.83 and a current ratio of 7.83. Millendo Therapeutics has a fifty-two week low of $6.77 and a fifty-two week high of $17.34.

Millendo Therapeutics Company Profile

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Further Reading: Liquidity

Get a free copy of the Zacks research report on Millendo Therapeutics (MLND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.